Immunex regulatory update

The Oncologic Drugs Advisory Committee agreed that Novantrone (mitozantrone) offers a net clinical benefit for late-stage prostate cancer (see BioCentury Extra, Sept. 12). If the FDA formally clears Novantrone, it will be the first product approved to treat late-stage prostate cancer, IMNX said. ...